MONTPELLIER, France–(BUSINESS WIRE)–MedinCell (Paris:MEDCL):
No safety concern is anticipated that would prevent health authorities from assessing the use of Ivermectin against Covid-19 as a new indication
The expert review written by a prominent toxicologist is an assessment of ivermectin medical safety profile
It is based on an extensive analysis of over 350 articles plus clearly identified and accessible web sources
The analysis will be submitted shortly by the author for peer review to an internationally acknowledged journal
MedinCell is making this review available immediately at www.medincell.com/ivermectin
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.